Compositions and methods for treating cancer

Patent metadata

Field	Value
Publication number	US-2025236678-A1
Application number	US-202519029442-A
Country	US
Kind code	A1
Filing date	Jan 17, 2025
Priority date	Jun 18, 2018
Publication date	Jul 24, 2025
Grant date	—

Abstract

The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

First claim

1 . An antibody or antibody fragment that binds a human CD39 polypeptide and that is capable of inhibiting the ATPase activity of a soluble extracellular domain human CD39 polypeptide, wherein the antibody or antibody fragment comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NOS: 31 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NOS: 36 or 37.

2 - 40 . (canceled)

41 . A pharmaceutical composition comprising an antibody according to claim 1 , and a pharmaceutically acceptable carrier.

42 . A kit comprising the antibody or antibody fragment of claim 1 , optionally further comprising a labeled secondary antibody or antibody fragment that specifically recognizes the antibody or antibody fragment of claim 1 .

43 . A nucleic acid encoding a heavy and/or light chain of an antibody or antibody fragment of claim 1 .

44 . A recombinant host cell producing the antibody or antibody fragment of claim 1 .

45 . A method for the treatment or prevention of cancer in an individual in need thereof, the method comprising administering to the individual an effective amount of an antibody or antibody fragment of claim 1 .

46 . A method for reducing the ATPase activity of soluble CD39 protein in an individual, the method comprising administering to said patient an effective amount of an antibody or antibody fragment of claim 1 .

47 . The method of claim 46 wherein the individual has cancer.

48 . A method for increasing T, NK and/or B cell activity in a subject having a cancer, and/or for relieving adenosine-mediated inhibition of T, NK and/or B cell activity in a subject having a cancer, the method comprising administering to said subject an effective amount of an antibody or antibody fragment of claim 1 .

49 . A method for increasing the activation of dendritic cells in a subject having a cancer, and/or for restoring ATP-mediated activation of DC cells in a subject having a cancer, the method comprising administering to said subject an effective amount of an antibody or antibody fragment of claim 1 .

50 . The method of claim 45 , wherein the individual has detectable soluble CD39 protein.

51 . The method of claim 50 wherein the individual has detectable soluble CD39 protein in circulation, in tumor tissue and/or in tumor adjacent tissue.

52 . A method for the treatment or prevention of a cancer in an individual in need thereof, the method comprising:
a) detecting soluble CD39 protein in circulation and/or in the tumor environment, and b) upon a determination that soluble CD39 protein is comprised in circulation and/or the tumor environment, optionally at a level that is increased compared to a reference level, administering to the individual an antibody or antibody fragment of claim 1 .

53 . The method of claim 52 , wherein detecting soluble CD39 protein comprises obtaining from the individual a biological sample, bringing said sample into contact with an antibody that binds soluble CD39 protein, and detecting antibody bound to soluble CD39 protein.

54 . The method of claim 45 , wherein the anti-CD39 antibody is administered at least once in an amount effective to achieve a concentration in blood (serum) and/or a tumor tissue that corresponds to at least the EC 50 for neutralization of the enzymatic activity of soluble CD39 protein.

55 . The method of claim 54 , wherein neutralization of the enzymatic activity of soluble CD39 protein is determined by assessing neutralization of ATPase activity of a CD39 extracellular domain protein in solution, by quantifying the reduction in ATP hydrolyzed when the CD39 protein is incubated with an anti-CD39 antibody or antibody fragment.

56 . The method of claim 45 , wherein the tumor or cancer is a solid tumor.

57 . The method of claim 56 , wherein the cancer is a head and neck squamous cell carcinoma, bladder cancer, ovarian cancer, colorectal carcinoma, melanoma, stomach cancer, esophageal cancer or a breast cancer.

Assignees

• Innate Pharma
• Orega Biotech

Inventors

• Chanteux Stéphanie
• Gauthier Laurent
• Gourdin Nicolas
• Paturel Carine
• Perrot Ivan
• Rossi Benjamin

Classifications

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/74

  Inducing cell proliferation · CPC title